LAB vs PFE · rev $174.4M vs P/E 20, rev $62.58B
Standard Biotools Inc (LAB) versus Pfizer Inc (PFE) — a side-by-side from cached financials, not a winner call.
Standard Biotools Inc (LAB) is a medical devices company listed on NASDAQ.
Pfizer Inc (PFE) is a drug manufacturers - general company listed on NYSE. It is led by Albert Bourla.
Latest reported LAB revenue for 2024-12-31 was $174.4M. Net income was -$138.9M. Revenue was up 64.0% from 2023-12-31 to 2024-12-31. LAB currently screens at market cap $317.1M.
Latest reported PFE revenue for 2025-12-31 was $62.58B. Net income was $7.77B. Revenue was down 1.6% from 2024-12-31 to 2025-12-31. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
LAB currently screens at market cap $317.1M. PFE currently screens at market cap $147.73B and trailing P/E 19.8.
Not investment advice. Open the LAB and PFE stock pages for the full models.
Not investment advice.